Advanced Hybrid Closed Loop System (AHCL) in Older Patients With Type 1 Diabetes Mellitus
Key claim: A 12-month randomized trial will test whether MiniMed 780G advanced hybrid closed-loop therapy versus continued MDI/CSII improves glucose indices, physical capacity, frailty and sarcopenia measures, quality of life, and cognition in older adults with type 1 diabetes.
Abstract
The trial is a randomized controlled, parallel group design study. Patients will be followed up during approximatively 12 months.
Patients will be randomized to either the MDI/CSII group which will continue their treatment as per routine procedures and the advanced Hybrid Closed Loop system (AHCL) group which will be connected to the Minimed 780G system. .
At the end of the 12 month study period, we will evaluate whether the AHCL system improved glucose indices in older individuals with Type 1 diabetes mellitus (T1DM) and assess whether the ACHL treatment improved physical capacity, frailty & sarcopenia indices as well as quality of life and cognitive functions.
Why this matters
A 12-month randomized trial will test whether MiniMed 780G advanced hybrid closed-loop therapy versus continued MDI/CSII improves glucose indices, physical capacity, frailty and sarcopenia measures, quality of life, and cognition in older adults with type 1 diabetes.